Abstract
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used, having numerous indications. However, despite their therapeutic role, they are associated with serious cardiovascular (CV) adverse events.
Objectives-Methods: This review comprising recent observational studies and metaanalyses over the past few years aims at updating the assessment of CV adverse events, namely stroke, myocardial infarction (MI), CV death, atrial fibrillation (AF), serious bleeding and heart failure related to the use of 4 of the most widely prescribed NSAIDs: ibuprofen, naproxen, diclofenac and mefenamic acid.
Results: The best safety profile related to MI was found for naproxen, while the worst safety profile, with excessively increased risk for stroke, MI and major bleeding, was for diclofenac. Naproxen showed higher risk for major bleeding than ibuprofen and the risk for stroke was slightly higher than ibuprofen. Regarding heart failure, ibuprofen presented the highest risk while the highest risk for AF was attributed to the current use of diclofenac. There are few data related to mefenamic acid, which showed a strong association with increased risk for stroke and a moderately increased risk for MI.
Conclusion: Further research is needed in order to devise new guidelines for safer use of NSAIDs.
Keywords: Cardiovascular, safety, adverse events, diclofenac, ibuprofen, naproxen, mefenamic acid, stroke, myocardial infarction.
Current Vascular Pharmacology
Title:Use of Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Relation to Cardiovascular Events. A Systematic Pharmacoepidemiological Review
Volume: 14 Issue: 6
Author(s): Christos Kontogiorgis, Ioannis Valikeserlis, Dimitra Hadjipavlou-Litina, Evangelia Nena and Theodoros C. Constantinidis
Affiliation:
Keywords: Cardiovascular, safety, adverse events, diclofenac, ibuprofen, naproxen, mefenamic acid, stroke, myocardial infarction.
Abstract: Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used, having numerous indications. However, despite their therapeutic role, they are associated with serious cardiovascular (CV) adverse events.
Objectives-Methods: This review comprising recent observational studies and metaanalyses over the past few years aims at updating the assessment of CV adverse events, namely stroke, myocardial infarction (MI), CV death, atrial fibrillation (AF), serious bleeding and heart failure related to the use of 4 of the most widely prescribed NSAIDs: ibuprofen, naproxen, diclofenac and mefenamic acid.
Results: The best safety profile related to MI was found for naproxen, while the worst safety profile, with excessively increased risk for stroke, MI and major bleeding, was for diclofenac. Naproxen showed higher risk for major bleeding than ibuprofen and the risk for stroke was slightly higher than ibuprofen. Regarding heart failure, ibuprofen presented the highest risk while the highest risk for AF was attributed to the current use of diclofenac. There are few data related to mefenamic acid, which showed a strong association with increased risk for stroke and a moderately increased risk for MI.
Conclusion: Further research is needed in order to devise new guidelines for safer use of NSAIDs.
Export Options
About this article
Cite this article as:
Kontogiorgis Christos, Valikeserlis Ioannis, Hadjipavlou-Litina Dimitra, Nena Evangelia and Constantinidis C. Theodoros, Use of Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Relation to Cardiovascular Events. A Systematic Pharmacoepidemiological Review, Current Vascular Pharmacology 2016; 14 (6) . https://dx.doi.org/10.2174/1570161114666160728093323
DOI https://dx.doi.org/10.2174/1570161114666160728093323 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Polyunsaturated Fatty Acids in Pregnancy and Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology Neuropeptide-Derived Antimicrobial Peptides from Invertebrates for Biomedical Applications
Current Medicinal Chemistry How to Investigate the Vascular Changes in Resistant Hypertension
Current Hypertension Reviews The Role of microRNAs in Cardiovascular Disease
Current Medicinal Chemistry ULK1 Plays a Critical Role in AMPK-Mediated Myocardial Autophagy and Contractile Dysfunction following Acute Alcohol Challenge
Current Pharmaceutical Design Naringenin and Atherosclerosis: A Review of Literature
Current Pharmaceutical Biotechnology LGE-MRI in the Assessment of Left-ventricular Remodelling in Myocarditis
Current Medical Imaging Synthesis, Antibacterial, and Cytotoxicity Evaluation of Oleanolic Acid-4-aminoquinoline Based Hybrid Compounds
Recent Advances in Anti-Infective Drug Discovery Characteristics of Brain Tumor Stem Cells and the Rationale for Applying Tyrosine Kinase Inhibitors as Potential Targeting Agents
Recent Patents on Regenerative Medicine Patent Review
Combinatorial Chemistry & High Throughput Screening Biomaterials and Mesenchymal Stem Cells for Regenerative Medicine
Recent Patents on Biotechnology New Antihypertensive Drugs Under Development
Current Medicinal Chemistry A Review on Hemisynthesis, Biosynthesis, Biological Activities, Mode of Action, and Structure-Activity Relationship of Podophyllotoxins: 2003- 2007
Current Medicinal Chemistry Hypertensive Left Ventricular Hypertrophy Regression: Does It Matter?
Current Hypertension Reviews The Effects of Microcystins (Cyanobacterial Heptapeptides) on the Eukaryotic Cytoskeletal System
Mini-Reviews in Medicinal Chemistry Stem Cells in Cardiovascular Regeneration: From Preservation of Endogenous Repair to Future Cardiovascular Therapies
Current Pharmaceutical Design The Controlled Release of Drugs and Bioactive Compounds from Mesoporous Silica Nanoparticles
Current Drug Delivery Aldosterone and Mineralocorticoid Receptor Antagonists on Pulmonary Hypertension and Right Ventricular Failure: A Review
Current Pharmaceutical Design Physiology, Pharmacology and Pathophysiology of the pH Regulatory Transport Proteins NHE1 and NBCn1: Similarities, Differences, and Implications for Cancer Therapy
Current Pharmaceutical Design Mechanisms And Prevention Of TAVI-Related Cerebrovascular Events
Current Pharmaceutical Design